news

Pfizer says its Covid-19 vaccine over 90 per cent effective in children ages 5 to 11

WASHINGTON (Oct 23): Pfizer and its partner BioNTech said their COVID-19 vaccine is safe and 90.7 per cent effective against symptomatic COVID-19 in children ages 5 to 11, Xinhua news agency reported.

The companies revealed the data in a document posted Friday ahead of a meeting of advisers to the United States Food and Drug Administration (FDA) scheduled for next Tuesday.

Pfizer and BioNTech are applying FDA emergency use authorisation (EUA) of a two-dose regimen of their 10-microgram dose for children ages 5 to 11. The two doses would be administered three weeks apart.

The data show that the two-dose primary series of the vaccine given to children from 5 to less than 12 years of age confers a high degree of protective efficacy against COVID-19 during a period when the Delta variant of concern predominates in the US.

The FDA's Vaccines and Related Biological Products Advisory Committee is scheduled to meet on Oct 26 to discuss whether to authorise the vaccine for children ages 5 to 11.

If authorised, it would be the first COVID-19 vaccine for younger children.

The Pfizer-BioNTech vaccine is currently fully approved for people ages 16 and older, and has an EUA for children ages 12 to 15.

Get the latest news @ www.EdgeProp.my

Subscribe to our Telegram channel for the latest stories and updates 

Click here for more property stories

Looking for properties to buy or rent? With >150,000 exclusive listings, including undervalued properties, from vetted Pro Agents, you can now easily find the right property on Malaysia's leading property portal EdgeProp! You can also get free past transacted data and use our proprietary Edge Reference Price tool, to make an informed purchase.
SHARE
RELATED POSTS
  1. Ensure teens keep their Covid-19 vaccine 2nd dose appointments, says Dr Noor Azmi
  2. Covid-19: Over 22.3 million Malaysian adults fully vaccinated as of Oct 31
  3. No mixing of booster shots for Pfizer recipients, decision on AstraZeneca soon, says Khairy